Author

Alun Parsons

University of Helsinki

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:CUT&Tag· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Caroline Akemi HeckmaniD· 3 shared Ana Rio‐MachíniD· 2 shared Csaba BödöriD· 2 shared Findlay Bewicke‐CopleyiD· 2 shared John G. GribbeniD· 2 shared Jude FitzgibboniD· 2 shared Juho Jalmari MiettineniD· 2 shared Kevin Rouault‐PierreiD· 2 shared

Activity by Year

2023-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Caroline Akemi HeckmanORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Targeting AML Resistance with Two Novel Combinations Demonstrate Superior Efficacy in TP53, HLA-B, MUC4 and FLT3 mutations

Elham Gholizadeh, Ehsan Zangene, Alun Parsons, Mika Kontro, Caroline Akemi Heckman, Mohieddin Jafari

This study evaluates two drug combinations for AML treatment, showing improved efficacy over venetoclax-based therapy in specific mutation profiles.

Biomedicine & Pharmacotherapy · Oct 13, 2025Peer-reviewedCancer Biology

DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes

Fadimana Kaya, Findlay Bewicke‐Copley, Juho Jalmari Miettinen, Pedro Casado, Eve Leddy, Özgen Deniz, Vincent‐Philippe Lavallée, Céline Philippe, Jiexin Zheng, Florian Grebien, Naeem Khan, Szilvia Krizsán, Joseph J Saad, Alexis Nolin-Lapalme, Josée Hébert, , Ana Rio‐Machín

This study identifies DEK::NUP214 as an XPO1-dependent transcriptional activator of leukemia genes, showing selective response to XPO1 inhibitors in t(6;9) AML cases.

Leukemia · Apr 9, 2025Peer-reviewedCancer Biology

Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes

Pedro Casado, Ana Rio‐Machín, Juho Jalmari Miettinen, Findlay Bewicke‐Copley, Kevin Rouault‐Pierre, Szilvia Krizsán, Alun Parsons, Vinothini Rajeeve, Farideh Miraki‐Moud, David Christopher Taussig, Csaba Bödör, John G. Gribben, Caroline Akemi Heckman, Jude Fitzgibbon, Pedro R. Cutillas

The paper identifies two distinct subgroups of KMT2A-rearranged AML using phosphoproteomics and shows different drug response profiles.

Signal Transduction and Targeted Therapy · Feb 26, 2023Peer-reviewedMolecular Biology